D Strubel

Publications (15)37.43 Total impact

• Article: [Consensus statement on severe dementia].

  B Vellas, S Gauthier, H Allain, S Andrieu, J-P Aquino, G Berrut, M Berthel, F Blanchard, V Camus, J F Dartigues, [......], F Nourhashemi, P J Ousset, J Pariente, A S Rigaud, P Robert, G Ruault, D Strubel, J Touchon, M Verny, J M Vetel
  [show abstract] [hide abstract]
  ABSTRACT: Under the auspices of the French Society of Gerontology and Geriatrics, a multidisciplinary group of experts, including geriatricians, neurologists, epidemiologists, psychiatrists, pharmacologists, and public health specialists developed consensus recommendations about care for patients with severe dementia. They defined 21 recommendations for general practitioners, long-term care physicians, and specialists, based on the knowledge currently available (2005). The aim of care at all stages is to mitigate the quality-of-life of patient, caregiver, and family insofar as possible, combining care and future planning until the end of life. Management, to take into account problems including nutritional status, behavior disorders, and ability (or inability) to perform activities of daily living, must be global, multidisciplinary, and coordinated and must optimize use of local medical and social resources. The group also stressed the importance of clinical research to improve knowledge of disease course and assess management strategies and recommended specific area for research.
  La Presse Médicale 12/2005; 34(20 Pt 1):1545-55. · 0.67 Impact Factor
• Article: Molecular forms of somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with senile dementia of the Alzheimer type.

  M Strittmatter, H Cramer, C Reuner, D Strubel, G Hamann, K Schimrigk
  [show abstract] [hide abstract]
  ABSTRACT: In the cerebrospinal fluid (CSF) of 53 patients with senile dementia of the Alzheimer type (SDAT) and 12 elderly controls, we measured somatostatin (SLI) and its molecular forms: high-molecular weight form (HMV-SST), somatostatin-14 (SST-14), somatostatin-25/28 (SST-28/25), and des-ala-somatostatin (des-ala-SST) using high pressure liquid chromatography (HPLC) and a radioimmunoassay. In SDAT, SLI was significantly decreased (p < 0.05) and correlated with dementia scores (r = -0.65, p < 0.05). HPLC separation showed a marked heterogeneity of SLI in the CSF with a preponderance of SST-14 and SST-25/28. The significant loss of SST-14 (p < 0.05) in SDAT was found to be correlated with dementia scores (r = 0.65). Moreover, qualitative and quantitative changes in the molecular pattern of SLI in SDAT indicated dysregulated synthesis and/or processing of somatostatin relating to the severity of dementia. The long-term administration of neuroleptics in severe cases of SDAT caused a significant increase of SLI (p < 0.05) and influenced the ratio of HMV-SST/SST-14 and SST25/28/SST-14.
  Biological Psychiatry 07/1997; 41(11):1124-30. · 8.28 Impact Factor
• Article: Neurochemical parameters in senile dementia of the Alzheimer type. A longitudinal study in four cases.

  M Strittmatter, G Hamann, H Cramer, C Reuner, F Kuntzmann, D Strubel
  European Archives of Psychiatry and Clinical Neuroscience 02/1996; 246(2):110-11. · 3.49 Impact Factor
• Article: Neurochemical parameters in senile dementia of the Alzheimer type

  M. Strittmatter, G. Hamann, H. Cramer, C. Reuner, F. Kuntzmann, D. Strubel
  European Archives of Psychiatry and Clinical Neuroscience 01/1996; 246(2):110-111. · 3.49 Impact Factor
• Article: Somatostatin-like immunoreactivity, its molecular forms and monoaminergic metabolites in aged and demented patients with Parkinson's disease--effect of L-Dopa.

  M Strittmatter, G F Hamann, D Strubel, H Cramer, K Schimrigk
  [show abstract] [hide abstract]
  ABSTRACT: There is some evidence that Parkinson's disease (PD) seems to be a heterogenous and generalized brain disorder reflecting a degeneration of multiple neuronal networks, including somatostatinergic neurons. Somatostatin-like immunoreactivity (SLI) and its molecular forms, high molecular weight form (HMV-SST), somatostatin-14 (SST-14), somatostatin-25/28 (SST-25/28) and Des-ala-somatostatin (Des-ala-SST), as well as homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5-HIAA) were estimated using HPLC and radioimmunoassay in the cerebrospinal fluid (CSF) of 35 aged parkinsonian patients with different stages of intellectual deterioration. The influence of L-dopa-treatment on these neurochemical parameters was evaluated. Without a correlation with dementia scores (p = 0.11), SLI was significantly reduced in PD in comparison to the control group (p < 0.05). The reduction was related to the progression of the disease. Correlations between SLI, HVA and 5-HIAA indicate a heterogenous brain disorder in PD with alterations of several transmitter systems and functions. Complex qualitative and quantitative changes in the molecular pattern of SLI are compatible with a dysregulated synthesis and/or posttranslational processing. L-dopa-treatment was associated with a significant increase of HVA (p < 0.05) and HMV-SST (p < 0.05) and a slight, but insignificant increase of SLI (p = 0.11).
  Acta Neurovegetativa 01/1996; 103(5):591-602. · 2.73 Impact Factor
• Article: [Dexamethasone suppression test in elderly demented patients. Role of the nutritional factor].

  M Ebel, D Strubel, A Muller-Balland, M Berthel, F Kuntzmann
  La Presse Médicale 10/1990; 19(29):1369. · 0.67 Impact Factor
• Article: [Bucco-linguo-facial dyskinesia in the aged subject. An epidemiologic survey of 614 aged persons].

  D Strubel, S Bimboes, F Kuntzmann, M Berthel
  La Presse Médicale 04/1990; 19(9):431-2. · 0.67 Impact Factor
• Article: Somatostatin-like immunoreactivity in the cerebrospinal fluid of aged patients with Parkinson's disease. The effect of dopatherapy.

  H Masson, I Popescu, D Strubel, H Cramer, F Kuntzmann
  [show abstract] [hide abstract]
  ABSTRACT: Cerebrospinal fluid (CSF) somatostatin concentrations were measured in 35 aged patients with Parkinson's disease (mean age, 79.5 years) and 11 control subjects (mean age, 82.3 years). In patients with Parkinson's disease the levels of somatostatin-like immunoreactivity were lower than in controls (P less than .02); these values were lowest in the untreated group. Somatostatin-like immunoreactivity levels in the CSF tended to increase with treatment but not significantly (P = .11). Somatostatin values were not correlated to age, sex, or duration of the disease. Somatostatin concentrations tended to be lower in more severely affected patients with higher scores on the Hoehn and Yahr (P = .13) and Webster staging scales (P = .13) and lower scores on Mini-Mental State (P = .10), but without statistical significance for these correlations.
  Journal of the American Geriatrics Society 02/1990; 38(1):19-24. · 3.74 Impact Factor
• Article: Frequency and causes of bucco-lingual-facial dyskinesias in the elderly.

  D Strubel, S Bimboes, F Kuntzmann, M Berthel
  The International journal of risk & safety in medicine 01/1990; 1(2):164-5.
• Article: Immunoreactive substance P and somatostatin in the cerebrospinal fluid of senile parkinsonian patients.

  H Cramer, K Rissler, N Rösler, D Strubel, D Schaudt, F Kuntzmann
  [show abstract] [hide abstract]
  ABSTRACT: The concentration of substance-P-like immunoreactivity (SPLI) and somatostatin-like immunoreactivity (SLI) in the lumbar spinal fluid of senile parkinsonian patients (mean age 77.6 +/- 6.7 years) and senile control patients (mean age 83.5 +/- 5.6 years) were determined by specific radioimmunoassays. Mean SPLI and SLI levels in the control group were 8.1 +/- 2.0 (SD) and 32.5 +/- 12.0 fmol/ml, respectively. The mean SPLI levels were not significantly different in the groups. The mean SLI level was significantly lower in the group of patients with Parkinson's disease (19.8 +/- 9.0 fmol/ml). A comparison with results in patients with senile dementia of Alzheimer type (SDAT) shows that, in addition to clinical and pathological correlations, Parkinson's disease of late onset may share a deficit in somatostatinergic neuromodulation with SDAT.
  European Neurology 02/1989; 29(1):1-5. · 1.81 Impact Factor
• Article: Comparison of DSIP- (delta sleep-inducing peptide) and P-DSIP-like (phosphorylated) immunoreactivity in cerebrospinal fluid of patients with senile dementia of Alzheimer type, multi-infarct syndrome, communicating hydrocephalus and Parkinson's disease.

  A Ernst, H Cramer, D Strubel, F Kuntzmann, G A Schoenenberger
  [show abstract] [hide abstract]
  ABSTRACT: The concentrations of delta sleep-inducing peptide (DSIP)-like (DSIP-LI) and P-DSIP-like (phosphorylated, Ser7) immunoreactivity (P-DSIP-LI) were measured by specific radioimmunoassay in the cerebrospinal fluid (CSF) of patients with senile dementia of the Alzheimer type [SDAT, subdivided into early (S1), middle (S2) and late dementia (S3)], multi-infarct dementia (MD), Parkinson's disease (PD), vascular disease (VD) and communicating hydrocephalus (H), as well as in control patients (C1, C2). Mean DSIP-LI and P-DSIP-LI concentrations were found to be significantly higher in the elderly control group (C1, mean age 83 +/- 5 years) than in the middle-aged control group (C2, mean age 40 +/- 16 years). DSIP-LI and P-DSIP-LI were positively correlated with age in both control groups. Significant decreases of DSIP-LI compared with age-matched controls (C1) were observed for S2, S3, MD, PD, VD and H. In contrast, no significant differences corresponding to pathology were found for P-DSIP-LI.
  Journal of Neurology 11/1987; 235(1):16-21. · 3.47 Impact Factor
• Article: Molecular size distribution of somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with degenerative brain disease.

  K Rissler, H Cramer, D Schaudt, D Strubel, W F Gattaz
  [show abstract] [hide abstract]
  ABSTRACT: The molecular size distribution of somatostatin-like immunoreactivity (SLI) in the cerebrospinal fluid (CSF) of patients with brain disease was investigated by separation with a Sephadex G-25 superfine column and subsequent radioimmunoassay of the eluate. Marked heterogeneity of SLI in the CSF of control subjects as well as in demented patients, was observed. Controls and schizophrenics exhibited an SLI distribution pattern consisting mainly of two pronounced peaks: the first eluting with the void volume of the column; the second being compatible with a peptide of N-terminally extended somatostatin-14. SLI from the CSF of patients with senile dementia of the Alzheimer type (SDAT), multi-infarct dementia (MID) and normal pressure hydrocephalus (NPH) showed the same two peaks found in controls and schizophrenics; and in addition, a third peak co-eluting with somatostatin-14. However, this peak was more pronounced in patients with SDAT and MID than in patients with NPH. Re-chromatography of G-25 sf void volume immunoreactivity afforded two fractions of an apparent molecular weight of about 10,000 daltons and 15,500 daltons, respectively.
  Neuroscience Research 03/1986; 3(3):213-25. · 2.25 Impact Factor
• Article: Somatostatin-like immunoreactivity and substance-P-like immunoreactivity in the CSF of patients with senile dementia of Alzheimer type, multi-infarct syndrome and communicating hydrocephalus.

  H Cramer, D Schaudt, K Rissler, D Strubel, J M Warter, F Kuntzmann
  [show abstract] [hide abstract]
  ABSTRACT: The concentrations of somatostatin-like immunoreactivity (SLI) and substance-P-like immunoreactivity (SPLI) in lumbar spinal fluid of patients with senile dementia of the Alzheimer type (SDAT), multi-infarct syndrome, communicating hydrocephalus and control patients were determined by specific radio-immunoassay. Mean SLI and SPLI levels were significantly lower in an aged control patient group (mean age 83.5 +/- 5.6 years) than in an adult control patient group (mean age 30.8 +/- 10 years). In the latter group SPLI levels correlated negatively with age. Mean SLI levels decreased with deterioration in SDAT patients by up to 33% in late dementia. SPLI correlated with SLI in SDAT patients but was decreased significantly only in late dementia patients. Moderate and insignificant decreases of SLI were observed in patients with multi-infarct syndrome or communicating hydrocephalus. Analysis of SLI by gel-permeation chromatography revealed molecular heterogeneity of SLI. At least four peaks of SLI were eluted, two of which had apparent molecular weights of about 10,000 and 15,500, possibly representing somatostatin precursors. The ratio of SRIF to SLI of higher molecular weight was increased in patients with dementia compared to control patients.
  Journal of Neurology 02/1985; 232(6):346-51. · 3.47 Impact Factor
• Article: Consensus statement on dementia of Alzheimer type in the severe stage.

  B Vellas, S Gauthier, H Allain, S Andrieu, J P Aquino, G Berrut, M Berthel, F Blanchard, V Camus, J F Dartigues, [......], F Nourhashemi, P J Ousset, J Pariente, A S Rigaud, P Robert, G Ruault, D Strubel, J Touchon, M Verny, J M Vetel
  The Journal of Nutrition Health and Aging 9(5):330-8. · 2.69 Impact Factor
• Article: Consensus sur la démence de type Alzheimer au stade sévère

  B. Vellas, S. Gauthier, H. Allain, S. Andrieu, J.-P. Aquino, G. Berrut, M. Berthel, F. Blanchard, V. Camus, J.-F. Dartigues, [......], F. Nourhashemi, P.-J. Ousset, J. Pariente, A.-S. Rigaud, P. Robert, G. Ruault, D. Strubel, J. Touchon, M. Verny, J.-M. Vetel
  [show abstract] [hide abstract]
  ABSTRACT: Under the auspices of the French Society of Gerontology and Geriatrics, a multidisciplinary team including geriatritians, neurologists, epidemiologists, psychiatrists, pharmacologists and public health specialists developed a consensus on care for patients with severe dementia. They defined 21 recommendations for general practitioners, long-term care physicians and specialists based on knowledge available in 2005. At all stages of the disease, the objective of care is to improve as much as possible quality-of-life for the patient and his/her family, including a life project until the end of life. It is always possible to do something for these patients and their family: nutritional status, behavior disorders, and incapacities to deal with basic activities of daily life have to be taken in consideration. Ressource allocation and proximity care have to be targeted. Research areas necessary to improve the care of patients with severe dementia has been selected.
  Revue Neurologique.